Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

the agreement, we obtained the exclusive U.S. rights to NexMed's topically applied alprostadil cream for the treatment of erectile dysfunction. We paid a license fee of $0.5 million which was recognized in R&D expense in the fourth quarter of 2007. The increase in our R&D activities, excluding the $0.5 million payment to NexMed, was $3.8 million, or 52.7%, which was mainly due to costs incurred in connection with clinical studies for two new oral contraceptives. We completed the enrollment of the first clinical study for a low-dose oral contraceptive in July 2007 and we completed enrollment of another clinical study for an oral contraceptive in December 2007.

Net Interest Expense

Interest expense, less interest income ("Net Interest Expense") for the quarter ended December 31, 2007 was $27.3 million, a decrease of $32.9 million, or 54.7%, from $60.2 million in the prior year quarter. The quarter ended December 31, 2007 included a $1.6 million write-off of deferred loan costs associated with an optional prepayment of $90.0 million under our senior secured credit facility. In the quarter ended December 31, 2006, the Company paid a premium in the amount of $18.4 million in connection with the optional redemption of $210.0 million of our 8.75% Senior Subordinated Notes ("Notes"). As a result of the optional redemption, the quarter ended December 31, 2006 included an $8.0 million write-off of deferred loan costs associated with the Notes. The quarter ended December 31, 2006 also included a $1.1 million write- off of deferred loan costs associated with an optional prepayment of $50.0 million under our senior secured credit facility. Excluding the premium payment and the write-offs of deferred loan costs, Net Interest Expense decreased $7.0 million, or 21.7%, in the current quarter. The decrease was primarily the result of reductions in outstanding debt which reduced the weighted average debt outstanding in the quarter ended December 31, 2007, as compared to
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
(Date:7/27/2015)... 2015 According to the new Market ... Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by ... , Asia-Pacific , Rest of the ... media market was valued at $247.7 million in 2014, which ... at a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/27/2015)... 2015 Junto Health, a company that helps ... develop new technology solutions, today announced the launch of ... leader in health care policy consulting. Working together with ... collaborative innovation process while, at the same time, they ... policy, health care finance and the delivery of health ...
Breaking Biology Technology:Brady Releases “3 Roads to GHS Labels” Video 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... Vicus Therapeutics, LLC, an,oncology-focused, clinical-stage, biopharmaceutical ... Clinical Research and Development, is,scheduled to present ... Tri-Conference on March 28st at 1:35 p.m. ... San Francisco. Dr. Rao will focus on,considerations ...
... to HistoRx AQUA(R) ... for tissue biomarker analysis-, NEW HAVEN, Conn., March ... a three-year agreement with Eli Lilly and Company,(NYSE: ... tissue biomarker,analysis widely available to Lilly researchers and clinicians ...
... company on track for Phase I/II trial ... ... Genetics Inc.,(TSX: SBS), a biotechnology company developing a portfolio of therapeutic,proteins ... toxicology study in animals to demonstrate the safety and,comparability of its ...
Cached Biology Technology:HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 2HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 3SemBioSys initiates toxicology study for safflower-produced insulin 2SemBioSys initiates toxicology study for safflower-produced insulin 3
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... French . Montreal, April 27, 2010 - Chagas ... world. It affects more than 10 million people, primarily in the ... year. A reliable and rapid diagnosis is the key in the ... impossible. Dr. Momar Ndao and his team at the Research Institute ...
... of microbes living underground could determine the amount of carbon ... a study published online this week in Nature Geoscience ... the Yale School of Forestry & Environmental Studies have found ... efficient over time in converting carbon in soil into carbon ...
... J. Sejnowski, Ph.D., whose work on neural networks helped ... 1980s, has been elected a member of the National ... during its 147th annual meeting in Washington, DC. Election ... original research, and is considered one of the highest ...
Cached Biology News:Major breakthrough in the diagnosis of parasitic diseases 2Microbes contribute less to climate warming 2Salk scientist Terrence Sejnowski elected to National Academy of Sciences 2
...
...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
... is suitable for use with ... incubating with 0.1% diethylpyrocarbonate (DEPC) ... the DEPC.DNase/RNase-Free Distilled WaterDistilled Water ... all molecular biology applications. It ...
Biology Products: